A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology.

AIMS The objective of this study was to evaluate the potential uses of relative abundance, relative activity approaches and inhibitory monoclonal antibodies (mAbs) in the characterization of CYP enzymology in early drug discovery. METHODS Intrinsic clearance estimates for the oxidation of ethoxyresorufin (a selective probe of CYP1A2 activity), tolbutamide (CYP2C9), S-mephenytoin (CYPC19), dextromethorphan (CYP2D6) and testosterone (CYP3A4) were used to determine relative activity factors (RAFs). CLint values were determined for the metabolism of 14 drugs in human liver microsomes (HLM) and for these major CYPs. The relative contribution of each individual CYP to the oxidation of each drug was then assessed using relative abundance and activity techniques in addition to inhibitory mAbs. RESULTS Relative abundance and activity methods as well as inhibitory mAbs qualitatively assigned the same CYP isoform as predominantly responsible for the clearance of each drug by HLM. Metabolism catalysed by CYP1A2, 2C9, 2D6 and 3A4 was also predicted to be quantitatively similar using both abundance and activity techniques. However, the relative contribution of the polymorphic CYP2C19 appeared to be over-estimated approximately two-fold using recombinant CYP compared with that from the HLM and mAb approach. CONCLUSIONS All three methods investigated in this study appear suitable for use in the characterization of the CYP metabolism of new chemical entities produced during early drug discovery.

[1]  P M Shaw,et al.  Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. , 1997, The Journal of pharmacology and experimental therapeutics.

[2]  Kaoru Kobayashi,et al.  Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.

[3]  Riley Rj.  The potential pharmacological and toxicological impact of P450 screening. , 2001 .

[4]  D. Waxman,et al.  Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. , 1988, Archives of biochemistry and biophysics.

[5]  F. Gonzalez,et al.  A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism. , 1997, Pharmacogenetics.

[6]  D. Greenblatt,et al.  Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. , 1998, Journal of pharmaceutical sciences.

[7]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[8]  D. Greenblatt,et al.  Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In‐vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A , 1998, The Journal of pharmacy and pharmacology.

[9]  Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[10]  A. D. Rodrigues,et al.  Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. , 1999, Biochemical pharmacology.

[11]  Peter J. Eddershaw,et al.  Advances in in vitro drug metabolism screening , 1999 .

[12]  F. Gonzalez,et al.  Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[13]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[14]  H. Yamazaki,et al.  Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[15]  K. Korzekwa,et al.  Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. , 1995, Biochemical pharmacology.

[16]  J S Harmatz,et al.  Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[17]  Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. , 1998, Pharmacogenetics.

[18]  H. Yamazaki,et al.  Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[19]  C. Crespi.  Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research , 1995 .

[20]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[21]  M. Wester,et al.  Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. , 1998, Archives of biochemistry and biophysics.

[22]  D. Greenblatt,et al.  Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. , 2001, The Journal of pharmacology and experimental therapeutics.

[23]  J. Houston,et al.  In vivo clearance of ethoxycoumarin and its prediction from In vitro systems. Use Of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[24]  D. Greenblatt,et al.  Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. , 2000, The Journal of pharmacology and experimental therapeutics.

[25]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[26]  K. Korzekwa,et al.  Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. , 2000, European journal of pharmacology.

[27]  R J Riley,et al.  Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[28]  Aiming Yu,et al.  Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[29]  R. Riley,et al.  Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[30]  M. Wester,et al.  CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.